Skip to main content
. 2021 Feb 2;4(1):372–385. doi: 10.1021/acsptsci.0c00217

Figure 5.

Figure 5

Calpain and cathepsin inhibitors mitigate loss of cell viability and tight junction proteins in ALDH2–/– BECs. Representative images (A) and quantitative analysis of (B) cell count (confluence normalized as %) or (C) LDH release of WT and ALDH2–/– BECs subjected to 0, 30, 60, and 120 min of OGD-R. (D) LDH release of ALDH2–/– BECs after 1 h of OGD-R and cotreatment of 1 μM sulforaphane or 10 μM inhibitors. (E and F) Quantitative analysis of immunoblots of ALDH2–/– BECs subjected to 1 h of OGD-R and nontreated control probed with antibodies against ZO-1 (E) or occludin (F). (G–J) Quantitative analysis of immunoblots of BECs treated with inhibitors (10 μM) followed by 1 h of OGD-R versus nontreated controls probed for ZO-1 (G), occludin (H), or SBDP (145 kDa and 150 kDa analyzed in I and J, respectively). Data represent mean ± SD of at least n = 3 separate isolated cell preps analyzed by one-way ANOVA with Dunnett’s or Tukey’s multicomparison analysis: *, p < 0.05; **, p < 0.01; and ***, p < 0.001, versus no OGD-R control; #, p < 0.05; ##, p < 0.01; and ###, p < 0.001, versus OGD-R vehicle-treated.